Arcus Biosciences (NYSE:RCUS) released its quarterly earnings data on Tuesday. The company reported ($0.64) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.40) by ($0.24), Bloomberg Earnings reports. Arcus Biosciences had a negative return on equity of 22.72% and a negative net margin of 613.46%. The company had revenue of $1.75 million for the quarter, compared to analyst estimates of $4.54 million.
Arcus Biosciences stock traded down $0.03 during mid-day trading on Wednesday, hitting $6.72. The stock had a trading volume of 448,130 shares, compared to its average volume of 140,835. The firm’s 50-day moving average is $8.30. The firm has a market cap of $304.62 million, a PE ratio of -4.70 and a beta of 1.02. Arcus Biosciences has a 12 month low of $6.30 and a 12 month high of $16.06.
Several brokerages have recently commented on RCUS. Svb Leerink restated an “outperform” rating on shares of Arcus Biosciences in a report on Friday, May 3rd. ValuEngine upgraded Arcus Biosciences from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. Zacks Investment Research upgraded Arcus Biosciences from a “hold” rating to a “buy” rating and set a $9.25 target price on the stock in a report on Thursday, July 4th. Finally, Citigroup decreased their target price on Arcus Biosciences from $25.00 to $15.00 and set an “in-line” rating on the stock in a report on Wednesday, June 5th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. Arcus Biosciences presently has an average rating of “Buy” and an average target price of $16.56.
In other news, President Juan C. Jaen purchased 10,000 shares of the firm’s stock in a transaction that occurred on Monday, June 3rd. The shares were acquired at an average price of $8.25 per share, for a total transaction of $82,500.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, President Juan C. Jaen purchased 15,000 shares of the firm’s stock in a transaction that occurred on Friday, June 28th. The stock was purchased at an average price of $7.59 per share, for a total transaction of $113,850.00. The disclosure for this purchase can be found here. In the last quarter, insiders purchased 140,343 shares of company stock worth $1,120,078. 19.23% of the stock is owned by company insiders.
Arcus Biosciences Company Profile
Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing cancer immunotherapies in the United States. The company develops various programs targeting immuno-oncology pathways, including AB928, a dual adenosine receptor antagonist, which is in a Phase I/Ib clinical trial; and AB122, an anti-PD-1 antibody that is in Phase I clinical trial.
Recommended Story: Trading on Margin
Receive News & Ratings for Arcus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.